SCHEMBL5364049

SCHEMBL5364049

Cc1c(Br)ccc2c1C(=Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)C(=O)N2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 3/20 0.59
EGFR P00533 3/20 0.59
IGF1R P08069 1/20 0.59
CTRC Q99895 1/20 0.49
EEF2K O00418 1/20 0.48
SRC P12931 1/20 0.48
GAA P10253 1/20 0.47
PTGS1 P23219 3/20 0.45
PTGS2 P35354 3/20 0.45
RAF1 P04049 5/20 0.45
LRRK2 Q5S007 2/20 0.45
MAP1LC3B Q9GZQ8 2/20 0.45
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45
APH1B Q8WW43 1/20 0.45
NCSTN Q92542 1/20 0.45
APH1A Q96BI3 1/20 0.45
PSENEN Q9NZ42 1/20 0.45
NTRK1 P04629 1/20 0.45
ARAF P10398 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5360968 0.95 EGFR (0.54) ERBB2EGFRIGF1RCTRCEEF2K
SCHEMBL5367617 0.94 ERBB2 (0.53) ERBB2EGFRIGF1RCTRCEEF2K
SCHEMBL5358360 0.89 LRRK2 (0.47) ERBB2EGFRIGF1RRAF1LRRK2
SCHEMBL5366011 0.86 ERBB2 (0.61) ERBB2EGFRIGF1RRAF1LRRK2
SCHEMBL7136800 0.85 MAP1LC3B (0.56) EGFRRAF1LRRK2MAP1LC3BPSEN1
SCHEMBL5362776 0.84 ERBB2 (0.67) ERBB2EGFRIGF1RRAF1LRRK2
SCHEMBL5368765 0.84 ERBB2 (0.42) ERBB2EGFRIGF1RCTRCPTGS2
SCHEMBL7745840 0.84 ERBB2 (0.57) ERBB2EGFRIGF1RCTRCEEF2K
SCHEMBL7137544 0.84 LRRK2 (0.49) EGFRRAF1LRRK2MAP1LC3BPSEN1
SCHEMBL5358709 0.83 MAP1LC3B (0.63) EGFRRAF1LRRK2MAP1LC3BPSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ERBB2 19/4885EGFR 286/4885IGF1R 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.